{"groups":[{"description":"Patients who have failed or refused Gleevec (TM) therapy and will receive Donor Lymphocyte Infusion.\n\nDonor Lymphocyte Infusion: donor cells infused over 2 hrs at cell dose of 0.5 dx 10\\^8 CD3+T-cells/kg","id":"FG000","title":"Chronic Myelogenous Leukemia (CML)"},{"description":"Patients with non-CML or CML who have failed DLI and will receive Induction Chemotherapy + DLI.\n\nInduction Chemotherapy + DLI: Fludarabine 25 mg/m2 IV Cyclosphosphamide 60 mg/kg IV Donor Lymphocyte Infusion (DLI)","id":"FG001","title":"Non-CML or CML Failing Donor Lymphocyte Infusion"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"57"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"57"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"During the recruitment period of the study, the donor lymphocyte infusion (DLI) was reduced from 1.0 x 10\\^8 CD3+ T-cells/kg to 0.5 x 10\\^8 CD3+ T-cells/kg due to an excess rate and intensity of graft vs. host disease."}